Is Gene Therapy Back in Style for VCs? GenSight Lands $42M
LONDON Gene therapy start-up GenSight Biologics has raised €32 million (US$41.6 million) in a Series A funding, hinting that following on from the first European regulatory approval of a gene therapy and with an increasing volume of positive clinical data, this iconic field is now de-risked in the eyes of venture capital investors.
The money will fund the ophthalmology specialist until 2016, enabling it to advance two products into Phase II for the treatment of Leber's hereditary optic neuropathy (LHON) and of retinitis pigmentosa.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter